Champions Oncology, Inc. (CSBR)
- Previous Close
5.03 - Open
5.10 - Bid --
- Ask --
- Day's Range
5.06 - 5.10 - 52 Week Range
4.17 - 7.32 - Volume
953 - Avg. Volume
4,287 - Market Cap (intraday)
68.785M - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.72 - Earnings Date Mar 14, 2024 - Mar 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool. The company markets its products through internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
www.championsoncology.comRecent News: CSBR
Performance Overview: CSBR
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CSBR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CSBR
Valuation Measures
Market Cap
68.85M
Enterprise Value
72.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.39
Price/Book (mrq)
--
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
-10.60
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.76%
Return on Assets (ttm)
-17.48%
Return on Equity (ttm)
-388.65%
Revenue (ttm)
49.22M
Net Income Avi to Common (ttm)
-9.73M
Diluted EPS (ttm)
-0.72
Balance Sheet and Cash Flow
Total Cash (mrq)
4.47M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.13M
Research Analysis: CSBR
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: CSBR
Daily – Vickers Top Buyers & Sellers for 01/16/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/11/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.